Potassium Chloride
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Potassium Chloride: From Electrolyte Replacement to Renal Tubular Acidosis
One-Sentence Summary
Potassium chloride is a widely used potassium salt. The registration data supplied here does not state its approved indications, so “electrolyte replacement” is background knowledge rather than data from the Evidence Pack. The TxGNN model predicts it may be relevant to renal tubular acidosis, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied registration data |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Potassium chloride is a potassium replacement salt, and mechanistically it may be applicable where potassium is lost.
Distal renal tubular acidosis often causes urinary potassium wasting and low blood potassium (hypokalaemia). Potassium replacement could plausibly address that part of the condition.
There is an important caveat. Potassium chloride supplies no alkali, so it does not correct the underlying metabolic acidosis. The chloride load may even worsen hyperchloraemic acidosis. Alkali-based potassium salts such as potassium citrate or potassium bicarbonate are the more mechanistically coherent choice. This reasoning is background knowledge, not evidence from the supplied data. The high model score may partly reflect generic potassium-disorder associations rather than a specific therapeutic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Five registrations were listed in the data (20 in total). One entry appeared twice, leaving four distinct registrations. The approved-indication text is not stated in the registration data for any of them.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| H1888 (ACT 101) | Urirex-k 50mg/300mg | Tablet | Not stated |
| 85/23.4/3 | Sabax plasma vet 3000ml | Infusion | Not stated |
| E875 (ACT 101/1965) | Plasmalyte b 1000ml tfa3716 | Infusion | Not stated |
| Z/24/2 | St thomas cardioplegic 1000ml sxa3024 | Infusion | Not stated |
Available forms are oral (tablet) and injectable (infusion). Sabax Plasma Vet appears to be a veterinary product, so confirm its relevance before counting it towards human use.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but there are no clinical trials or publications for this drug-disease pair, and the mechanism of action, original indications and safety data are all missing. Potassium chloride also does not address the acidosis itself, and alkali-based potassium salts are the more logical option.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank
- Approved indication text for the SAHPRA registrations
- A targeted literature and trial search on potassium chloride versus alkali potassium salts in renal tubular acidosis
- Clarification of whether potassium chloride offers any advantage over potassium citrate or bicarbonate for this condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.